

# Pietro Ravani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/944608/publications.pdf>

Version: 2024-02-01

236  
papers

12,810  
citations

19608

61  
h-index

29081

104  
g-index

244  
all docs

244  
docs citations

244  
times ranked

13115  
citing authors

#	ARTICLE	IF	CITATIONS
1	Associations between Hemodialysis Access Type and Clinical Outcomes. Journal of the American Society of Nephrology: JASN, 2013, 24, 465-473.	3.0	560
2	Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nature Genetics, 2011, 43, 321-327.	9.4	528
3	Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nature Genetics, 2014, 46, 1187-1196.	9.4	505
4	Vitamin D levels and patient outcome in chronic kidney disease. Kidney International, 2009, 75, 88-95.	2.6	384
5	Asymmetrical Dimethylarginine Predicts Progression to Dialysis and Death in Patients with Chronic Kidney Disease: A Competing Risks Modeling Approach. Journal of the American Society of Nephrology: JASN, 2005, 16, 2449-2455.	3.0	352
6	Renal outcome in patients with congenital anomalies of the kidney and urinary tract. Kidney International, 2009, 76, 528-533.	2.6	309
7	Associations Between Acute Kidney Injury and Cardiovascular and Renal Outcomes After Coronary Angiography. Circulation, 2011, 123, 409-416.	1.6	309
8	Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease. Annals of Internal Medicine, 2010, 153, 23.	2.0	297
9	Pregnancy in CKD Stages 3 to 5: Fetal and Maternal Outcomes. American Journal of Kidney Diseases, 2007, 49, 753-762.	2.1	238
10	Overview of the Alberta Kidney Disease Network. BMC Nephrology, 2009, 10, 30.	0.8	221
11	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	0.8	221
12	Comparison of the Complexity of Patients Seen by Different Medical Subspecialists in a Universal Health Care System. JAMA Network Open, 2018, 1, e184852.	2.8	181
13	Short-Term Effects of Rituximab in Children with Steroid- and Calcineurin-Dependent Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1308-1315.	2.2	180
14	Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2014, 29, iv15-iv25.	0.4	180
15	The short- and long-term impact of multi-disciplinary clinics in addition to standard nephrology care on patient outcomes. Nephrology Dialysis Transplantation, 2005, 20, 147-154.	0.4	177
16	Timing and Outcome of Renal Replacement Therapy in Patients with Congenital Malformations of the Kidney and Urinary Tract. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 67-74.	2.2	174
17	The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2013, 29, 528-542.	0.8	163
18	Biology of arteriovenous fistula failure. Journal of Nephrology, 2007, 20, 150-63.	0.9	163

#	ARTICLE	IF	CITATIONS
19	Atheroembolic renal disease. <i>Lancet, The</i> , 2010, 375, 1650-1660.	6.3	156
20	Rituximab in Children with Steroid-Dependent Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2259-2266.	3.0	156
21	Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. <i>Gut</i> , 2014, 63, 552-558.	6.1	154
22	Rituximab in Children with Resistant Idiopathic Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1117-1124.	3.0	144
23	The Challenge of Diagnosing Atheroembolic Renal Disease. <i>Circulation</i> , 2007, 116, 298-304.	1.6	142
24	Nephrology Visits and Health Care Resource Use Before and After Reporting Estimated Glomerular Filtration Rate. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1151.	3.8	141
25	Predictors of Renal and Patient Outcomes in Atheroembolic Renal Disease: A Prospective Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1584-1590.	3.0	134
26	Trends in dialysis modality choice and related patient survival in the ERA-EDTA Registry over a 20-year period. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 120-128.	0.4	132
27	Rates of Treated and Untreated Kidney Failure in Older vs Younger Adults. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 2507-15.	3.8	128
28	Comparison of Patient Survival Between Hemodialysis and Peritoneal Dialysis Among Patients Eligible for Both Modalities. <i>American Journal of Kidney Diseases</i> , 2018, 71, 344-351.	2.1	126
29	The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. <i>BMJ, The</i> , 2015, 350, h246-h246.	3.0	125
30	Coexistence of Different Circulating Anti-Podocyte Antibodies in Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1394-1400.	2.2	123
31	Cardiovascular and Noncardiovascular Mortality among Men and Women Starting Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1722-1730.	2.2	117
32	Canadian Society of Nephrology 2014 clinical practice guideline for timing the initiation of chronic dialysis. <i>Cmaj</i> , 2014, 186, 112-117.	0.9	117
33	Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2483-2498.	3.0	112
34	Derivation and External Validation of Prediction Models for Advanced Chronic Kidney Disease Following Acute Kidney Injury. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1787.	3.8	112
35	Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. <i>Kidney International</i> , 2013, 84, 1025-1033.	2.6	109
36	Chronic kidney disease and life expectancy. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3182-3186.	0.4	103

#	ARTICLE	IF	CITATIONS
37	Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 972-982.	3.0	103
38	Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1888.	3.8	103
39	Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens. <i>Journal of Proteomics</i> , 2011, 74, 2008-2017.	1.2	101
40	Proteinuria and Rate of Change in Kidney Function in a Community-Based Population. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1661-1667.	3.0	97
41	Effects of comorbid and demographic factors on dialysis modality choice and related patient survival in Europe. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2940-2947.	0.4	96
42	Cardiovascular Comorbidity and Late Referral Impact Arteriovenous Fistula Survival: A Prospective Multicenter Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 204-209.	3.0	95
43	Examining the Association between Hemodialysis Access Type and Mortality: The Role of Access Complications. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 955-964.	2.2	95
44	Temporal Risk Profile for Infectious and Noninfectious Complications of Hemodialysis Access. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1668-1677.	3.0	91
45	Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. <i>Kidney International</i> , 2014, 86, 1244-1252.	2.6	91
46	Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. <i>Journal of Autoimmunity</i> , 2016, 74, 6-12.	3.0	89
47	Antiplatelet Therapy to Prevent Hemodialysis Vascular Access Failure: Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2013, 61, 112-122.	2.1	81
48	Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1028-1037.	0.4	81
49	Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. <i>Journal of Autoimmunity</i> , 2016, 74, 194-200.	3.0	80
50	Use of vascular access for haemodialysis in Europe: a report from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1956-1964.	0.4	79
51	Vascular access surgery managed by renal physicians: The choice of native arteriovenous fistulas for hemodialysis. <i>American Journal of Kidney Diseases</i> , 2002, 40, 1264-1276.	2.1	77
52	Patient Education and Peritoneal Dialysis Modality Selection: A Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2016, 68, 422-433.	2.1	77
53	Marginal structural models in clinical research: when and how to use them?. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, ii84-ii90.	0.4	75
54	The Effect of Predialysis Fistula Attempt on Risk of All-Cause and Access-Related Death. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 613-620.	3.0	73

#	ARTICLE	IF	CITATIONS
55	Incidence and Prognosis of Acute Kidney Diseases and Disorders Using an Integrated Approach to Laboratory Measurements in a Universal Health Care System. <i>JAMA Network Open</i> , 2019, 2, e191795.	2.8	73
56	Complications From Tunneled Hemodialysis Catheters: A Canadian Observational Cohort Study. <i>American Journal of Kidney Diseases</i> , 2019, 73, 467-475.	2.1	73
57	Lifetime Risk of ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1569-1578.	3.0	72
58	Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 710-720.	2.2	70
59	Accounting for Age in the Definition of Chronic Kidney Disease. <i>JAMA Internal Medicine</i> , 2021, 181, 1359.	2.6	70
60	Validating a case definition for chronic kidney disease using administrative data. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1826-1831.	0.4	68
61	Incident Renal Events and Risk Factors in Autosomal Dominant Polycystic Kidney Disease: A Population and Family-Based Cohort Followed for 22 Years. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 710-717.	2.2	67
62	Renal replacement therapy for rare diseases affecting the kidney: an analysis of the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, iv1-iv8.	0.4	65
63	Effect of a Low- Versus Moderate-Protein Diet on Progression of CKD: Follow-up of a Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2009, 54, 1052-1061.	2.1	64
64	Health Care Costs in People With Diabetes and Their Association With Glycemic Control and Kidney Function. <i>Diabetes Care</i> , 2013, 36, 1172-1180.	4.3	63
65	Analyzing hospitalization data: potential limitations of Poisson regression. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1244-1249.	0.4	62
66	Report of the Standardized Outcomes in Nephrology Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure for Hemodialysis Vascular Access. <i>American Journal of Kidney Diseases</i> , 2018, 71, 690-700.	2.1	62
67	Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2). <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1905-1924.	3.0	58
68	Regulatory T cells and minimal change nephropathy: in the midst of a complex network. <i>Clinical and Experimental Immunology</i> , 2016, 183, 166-174.	1.1	58
69	Outcomes of Male Patients with Alport Syndrome Undergoing Renal Replacement Therapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1969-1976.	2.2	56
70	Preemptive Correction of Arteriovenous Access Stenosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>American Journal of Kidney Diseases</i> , 2016, 67, 446-460.	2.1	56
71	Estimating Urine Albumin-to-Creatinine Ratio from Protein-to-Creatinine Ratio: Development of Equations using Same-Day Measurements. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 591-601.	3.0	55
72	Pregnancy and Progression of IgA Nephropathy: Results of an Italian Multicenter Study. <i>American Journal of Kidney Diseases</i> , 2010, 56, 506-512.	2.1	53

#	ARTICLE	IF	CITATIONS
73	Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Association–European Dialysis and Transplant Association Registry. <i>American Journal of Kidney Diseases</i> , 2015, 66, 613-620.	2.1	52
74	Mortality due to pulmonary embolism, myocardial infarction, and stroke among incident dialysis patients. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2484-2493.	1.9	48
75	Emergency Department Use among Patients with CKD: A Population-Based Analysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 304-314.	2.2	47
76	Randomized Crossover Trial of Blood Volume Monitoring–Guided Ultrafiltration Biofeedback to Reduce Intradialytic Hypotensive Episodes with Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1831-1840.	2.2	47
77	Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1238-1249.	1.1	46
78	Urine Creatinine Excretion and Clinical Outcomes in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1877-1883.	2.2	43
79	Estimated GFR and Fracture Risk. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1367-1376.	2.2	43
80	Changes in kidney function follow living donor nephrectomy. <i>Kidney International</i> , 2020, 98, 176-186.	2.6	41
81	Progression and Regression of Chronic Kidney Disease by Age Among Adults in a Population-Based Cohort in Alberta, Canada. <i>JAMA Network Open</i> , 2021, 4, e2112828.	2.8	41
82	The native arteriovenous fistula in 2007. Surveillance and monitoring. <i>Journal of Nephrology</i> , 2007, 20, 656-67.	0.9	41
83	Fistula-first and catheter-last: fading certainties and growing doubts. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 727-730.	0.4	40
84	Clinical Features and Long-Term Outcome of Nephrotic Syndrome Associated with Heterozygous NPHS1 and NPHS2 Mutations. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1065-1072.	2.2	38
85	Validation of a case definition to define chronic dialysis using outpatient administrative data. <i>BMC Medical Research Methodology</i> , 2011, 11, 25.	1.4	38
86	Long-term Kidney Transplant Outcomes in Primary Glomerulonephritis. <i>Transplantation</i> , 2016, 100, 1955-1962.	0.5	38
87	Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation. <i>American Journal of Kidney Diseases</i> , 2017, 69, 734-743.	2.1	38
88	Risk of death following kidney allograft failure: a systematic review and meta-analysis of cohort studies. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1778-1786.	0.4	37
89	Influence of Mortality on Estimating the Risk of Kidney Failure in People with Stage 4 CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2219-2227.	3.0	37
90	Multidisciplinary chronic kidney disease management improves survival on dialysis. <i>Journal of Nephrology</i> , 2003, 16, 870-7.	0.9	36

#	ARTICLE	IF	CITATIONS
91	Fistula maturation: doesn't time matter at all?. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 684-687.	0.4	35
92	Survival in dialysis patients is different between patients with diabetes as primary renal disease and patients with diabetes as a co-morbid condition. <i>Diabetologia</i> , 2013, 56, 1949-1957.	2.9	35
93	Homoarginine and Mortality in Pre-Dialysis Chronic Kidney Disease (CKD) Patients. <i>PLoS ONE</i> , 2013, 8, e72694.	1.1	35
94	Surgical salvage of the autogenous arteriovenous fistula (AVF). <i>Journal of Nephrology</i> , 2007, 20, 388-98.	0.9	35
95	Predictors of Treatment with Mastectomy, Use of Sentinel Lymph Node Biopsy and Upstaging to Invasive Cancer in Patients Diagnosed with Breast Ductal Carcinoma In situ (DCIS) on Core Biopsy. <i>Annals of Surgical Oncology</i> , 2014, 21, 66-73.	0.7	34
96	Impact of Modality Choice on Rates of Hospitalization in Patients Eligible for Both Peritoneal Dialysis and Hemodialysis. <i>Peritoneal Dialysis International</i> , 2014, 34, 41-48.	1.1	33
97	Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol. <i>BMJ Open</i> , 2017, 7, e013319.	0.8	32
98	Morphometric and Biological Characterization of Biofilm in Tunneled Hemodialysis Catheters. <i>American Journal of Kidney Diseases</i> , 2011, 57, 449-455.	2.1	31
99	The Duke Activity Status Index in Patients with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 573-580.	2.2	31
100	Optimizing the dialysate calcium concentration in bicarbonate haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2489-2496.	0.4	31
101	Time trend in access to the waiting list and renal transplantation: a comparison of four European countries. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3621-3631.	0.4	31
102	Potentially Preventable Hospitalization among Patients with CKD and High Inpatient Use. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2022-2031.	2.2	30
103	Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2652-2663.	3.0	30
104	Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy. <i>Journal of Nephrology</i> , 2009, 22, 152-9.	0.9	30
105	Clinical epidemiology of arteriovenous fistula in 2007. <i>Journal of Nephrology</i> , 2007, 20, 141-9.	0.9	29
106	Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosis. <i>Kidney International</i> , 2015, 87, 1223-1229.	2.6	28
107	Factors Influencing Permanent Catheter Performance. <i>Journal of Vascular Access</i> , 2001, 2, 106-109.	0.5	27
108	An Economic Evaluation of rt-PA Locking Solution in Dialysis Catheters. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2887-2895.	3.0	27



#	ARTICLE	IF	CITATIONS
109	Risk, Predictors, and Outcomes of Acute Kidney Injury in Patients Admitted to Intensive Care Units in Egypt. <i>Scientific Reports</i> , 2017, 7, 17163.	1.6	27
110	Interventional nephrology: from episodic to coordinated vascular access care. <i>Journal of Nephrology</i> , 2007, 20, 399-405.	0.9	27
111	The choice of the dialysate calcium concentration in the management of patients on haemodialysis and haemodiafiltration. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 37vii-40.	0.4	26
112	Association between pre-transplant dialysis modality and patient and graft survival after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4473-4480.	0.4	26
113	A population-based cohort study defines prognoses in severe chronic kidney disease. <i>Kidney International</i> , 2018, 93, 1217-1226.	2.6	26
114	Survival among older adults with kidney failure is better in the first three years with chronic dialysis treatment than not. <i>Kidney International</i> , 2018, 94, 582-588.	2.6	26
115	Association of Age With Risk of Kidney Failure in Adults With Stage IV Chronic Kidney Disease in Canada. <i>JAMA Network Open</i> , 2020, 3, e2017150.	2.8	26
116	Factors associated with unsuccessful utilization and early failure of the arterio-venous fistula for hemodialysis. <i>Journal of Nephrology</i> , 2005, 18, 188-96.	0.9	26
117	Autogenous arteriovenous fistula options. <i>Journal of Nephrology</i> , 2007, 20, 288-98.	0.9	26
118	Trends in Biopsy-Based Diagnosis of Kidney Disease: A Population Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2018, 5, 205435811879969.	0.6	25
119	Structured pre-dialysis programs: more than just timely referral?. <i>Journal of Nephrology</i> , 2003, 16, 862-9.	0.9	25
120	IgA Nephropathy: The Presence of Familial Disease Does Not Confer an Increased Risk for Progression. <i>American Journal of Kidney Diseases</i> , 2006, 47, 761-769.	2.1	23
121	Are Female Applicants Rated Higher Than Males on the Multiple Mini-Interview? Findings From the University of Calgary. <i>Academic Medicine</i> , 2017, 92, 841-846.	0.8	23
122	Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: experience in 2 Canadian provinces. <i>Canadian Journal of Surgery</i> , 2009, 52, 92-7.	0.5	23
123	Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study. <i>Pediatric Nephrology</i> , 2020, 35, 1437-1444.	0.9	22
124	Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney disease. <i>Kidney International</i> , 2008, 73, 95-101.	2.6	21
125	Proteinuria and Life Expectancy. <i>American Journal of Kidney Diseases</i> , 2013, 61, 646-648.	2.1	21
126	Rituximab vs Low-Dose Mycophenolate Mofetil in Recurrence of Steroid-Dependent Nephrotic Syndrome in Children and Young Adults. <i>JAMA Pediatrics</i> , 2021, 175, 631.	3.3	21



#	ARTICLE	IF	CITATIONS
127	Association between chronic conditions and perceived unmet health care needs. <i>Open Medicine</i> , 2012, 6, e48-58.	1.5	21
128	Barriers to Adopting a Fistula-First Policy in Europe: An International Survey among National Experts. <i>Journal of Vascular Access</i> , 2015, 16, 113-119.	0.5	20
129	The biobank for the molecular classification of kidney disease: research translation and precision medicine in nephrology. <i>BMC Nephrology</i> , 2017, 18, 252.	0.8	20
130	Renal Denervation Therapy for the Treatment of Resistant Hypertension: A Position Statement by the Canadian Hypertension Education Program. <i>Canadian Journal of Cardiology</i> , 2014, 30, 16-21.	0.8	19
131	ACCESS HD pilot: A randomised feasibility trial Comparing Catheters with fistulas in Elderly patients Starting haemodialysis. <i>BMJ Open</i> , 2016, 6, e013081.	0.8	19
132	Low-dose ofatumumab for multidrug-resistant nephrotic syndrome in children: a randomized placebo-controlled trial. <i>Pediatric Nephrology</i> , 2020, 35, 997-1003.	0.9	19
133	Vascular mapping techniques: advantages and disadvantages. <i>Journal of Nephrology</i> , 2007, 20, 299-303.	0.9	19
134	New insights into membranous glomerulonephritis: from bench to bedside. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2428-2430.	0.4	18
135	The effect of timing of the first kidney transplantation on survival in children initiating renal replacement therapy. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1256-1264.	0.4	18
136	Accounting for the Competing Risk of Death to Predict Kidney Failure in Adults With Stage 4 Chronic Kidney Disease. <i>JAMA Network Open</i> , 2021, 4, e219225.	2.8	18
137	Mortality and Morbidity in Kidney Transplant Recipients With a Failing Graft: A Matched Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812090867.	0.6	17
138	Measuring asymmetric dimethylarginine (ADMA) in CKD: a comparison between enzyme-linked immunosorbent assay and liquid chromatography-electrospray tandem mass spectrometry. <i>Journal of Nephrology</i> , 2012, 25, 1016-1022.	0.9	17
139	How to improve dialysis adequacy in patients with vascular access problems. <i>Journal of Vascular Access</i> , 2006, 7, 53-59.	0.5	16
140	A Pilot Study of IL2 in Drug-Resistant Idiopathic Nephrotic Syndrome. <i>PLoS ONE</i> , 2015, 10, e0138343.	1.1	16
141	Multi-Disciplinary Vascular Access Care and Access Outcomes in People Starting Hemodialysis Therapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1991-1999.	2.2	16
142	Clinical research of kidney diseases II: problems of study design. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2785-2794.	0.4	15
143	Clinical research of kidney diseases III: Principles of regression and modelling. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3422-3430.	0.4	15
144	Controversies and Concerns in Hemodialysis – Series Editor: Marcello Tonelli: What’s Next After ‘Fistula First’: Is an Arteriovenous Graft or Central Venous Catheter Preferable When an Arteriovenous Fistula Is Not Possible?. <i>Seminars in Dialysis</i> , 2009, 22, 539-544.	0.7	15

#	ARTICLE	IF	CITATIONS
145	Outcomes of the First and Second Hemodialysis Fistula: A Cohort Study. <i>American Journal of Kidney Diseases</i> , 2019, 73, 62-71.	2.1	15
146	Nephrology consultation and mortality in people with stage 4 chronic kidney disease: a population-based study. <i>Cmaj</i> , 2019, 191, E274-E282.	0.9	15
147	Quantifying the risk of insertion-related peritoneal dialysis catheter complications following laparoscopic placement: Results from the North American PD Catheter Registry. <i>Peritoneal Dialysis International</i> , 2020, 40, 185-192.	1.1	15
148	Italian randomized trial of hemoglobin maintenance to prevent or delay left ventricular hypertrophy in chronic kidney disease. <i>Journal of Nephrology</i> , 2008, 21, 861-70.	0.9	15
149	Development and External Validation of a Machine Learning Model for Progression of CKD. <i>Kidney International Reports</i> , 2022, 7, 1772-1781.	0.4	15
150	Association of Initiation of Dialysis With Hospital Length of Stay and Intensity of Care in Older Adults With Kidney Failure. <i>JAMA Network Open</i> , 2020, 3, e200222.	2.8	14
151	Factors Associated with Initiation of Chronic Renal Replacement Therapy for Patients with Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1327-1335.	2.2	13
152	Kidney Function, Albuminuria and Life Expectancy. <i>Canadian Journal of Kidney Health and Disease</i> , 2014, 1, 33.	0.6	13
153	Selection of peritoneal dialysis among older eligible patients with end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw367.	0.4	13
154	Association between perceived unmet health care needs and risk of adverse health outcomes among patients with chronic medical conditions. <i>Open Medicine</i> , 2013, 7, e21-30.	1.5	13
155	Technique Failure in Peritoneal Dialysis Patients: Insights and Challenges. <i>Peritoneal Dialysis International</i> , 2010, 30, 161-162.	1.1	12
156	Pre-emptive correction for haemodialysis arteriovenous access stenosis. <i>The Cochrane Library</i> , 2016, , CD010709.	1.5	12
157	Renal Function, Albuminuria, and the Risk of Cardiovascular Events After Kidney Transplantation. <i>Transplantation Direct</i> , 2018, 4, e389.	0.8	12
158	Modeling Survival of Arteriovenous Accesses for Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1243-1248.	2.2	11
159	Effectiveness and Cost of Weekly Recombinant Tissue Plasminogen Activator Hemodialysis Catheter Locking Solution. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 429-435.	2.2	11
160	COVID-19 screening of asymptomatic patients admitted through emergency departments in Alberta: a prospective quality-improvement study. <i>CMAJ Open</i> , 2020, 8, E887-E894.	1.1	11
161	Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e029232.	0.8	11
162	On Framing the Research Question and Choosing the Appropriate Research Design. <i>Methods in Molecular Biology</i> , 2008, 473, 1-17.	0.4	10

#	ARTICLE	IF	CITATIONS
163	Lack of Association between Dialysis Modality and Outcomes in Atheroembolic Renal Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 454-459.	2.2	10
164	Atrial fibrillation and chronic kidney disease: struggling through thick and thin: Table 1. <i>Nephrology Dialysis Transplantation</i> , 2016, 32, gfw378.	0.4	10
165	Ofatumumab-associated acute respiratory manifestations: clinical characteristics and treatment. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1146-1148.	1.1	10
166	Clinical research of kidney diseases 1: researchable questions and valid answers. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3681-3690.	0.4	9
167	Galectin-3 and New-Onset CKD: Marker or Mediator?. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1342-1344.	3.0	9
168	Ultrafiltration biofeedback guided by blood volume monitoring to reduce intradialytic hypotensive episodes in hemodialysis: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 483.	0.7	9
169	Central venous catheters for chronic hemodialysis: Is elast choice never the right choice?. <i>Seminars in Dialysis</i> , 2018, 31, 3-10.	0.7	9
170	Outcomes Following Macrolide Use in Kidney Transplant Recipients. <i>Canadian Journal of Kidney Health and Disease</i> , 2019, 6, 205435811983070.	0.6	9
171	Protocol for a pilot randomised controlled trial of an educational programme for adults on chronic haemodialysis with fatigue (Fatigue-HD). <i>BMJ Open</i> , 2019, 9, e030333.	0.8	9
172	Clinical research of kidney diseases IV: standard regression models. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 475-482.	0.4	8
173	Clinical research of kidney diseases V: extended analytic models. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 1484-1492.	0.4	8
174	Patterns of engagement with the health care system and risk of subsequent hospitalization amongst patients with diabetes. <i>BMC Health Services Research</i> , 2013, 13, 399.	0.9	8
175	Hemodialysis prescription education decreases intradialytic hypotension. <i>Journal of Nephrology</i> , 2013, 26, 315-322.	0.9	8
176	Clinical trials in minimal change disease. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i7-i13.	0.4	8
177	Mortality and Resource Use Among Individuals With Chronic Kidney Disease or Cancer in Alberta, Canada, 2004-2015. <i>JAMA Network Open</i> , 2022, 5, e2144713.	2.8	8
178	Incidence of melanoma in organ transplant recipients in Alberta, Canada. <i>Clinical Transplantation</i> , 2016, 30, 1271-1275.	0.8	7
179	Ofatumumab-associated acute pneumonitis: Not new but still the first case. <i>Pharmacology Research and Perspectives</i> , 2017, 5, e00267.	1.1	7
180	Pharmacological interventions for heart failure in people with chronic kidney disease. <i>The Cochrane Library</i> , 2020, 2020, CD012466.	1.5	7

#	ARTICLE	IF	CITATIONS
181	NSAID prescriptions in kidney transplant recipients. <i>Clinical Transplantation</i> , 2021, 35, e14405.	0.8	7
182	American Society of Diagnostic and Interventional Nephrology Section Editor: Stephen Ash: Arteriovenous Fistula Surgery: An American Perspective from Italy. <i>Seminars in Dialysis</i> , 2005, 18, 542-549.	0.7	6
183	The effect of citrate dialysate on intradialytic heparin dose in haemodialysis patients: study design of a randomised controlled trial. <i>BMC Nephrology</i> , 2015, 16, 147.	0.8	6
184	Citrate vs. acetate dialysate on intradialytic heparin dose: A double blind randomized crossover study. <i>Hemodialysis International</i> , 2016, 20, 537-547.	0.4	6
185	Association between Duration of Predialysis Care and Mortality after Dialysis Start. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 893-899.	2.2	6
186	The Influence of Age on the Likelihood of Catheter-Free Fistula Use in Hemodialysis Patients. <i>Canadian Journal of Kidney Health and Disease</i> , 2019, 6, 205435811986194.	0.6	6
187	Sex differences in the vascular access of hemodialysis patients: a cohort study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1412-1418.	1.4	6
188	The native arteriovenous fistula in 2007. Research needs. <i>Journal of Nephrology</i> , 2007, 20, 668-73.	0.9	6
189	Calculated versus measured albumin-creatinine ratio to predict kidney failure and death in people with chronic kidney disease. <i>Kidney International</i> , 2022, 101, 1260-1270.	2.6	6
190	Calculating the Rate of Senescence From Mortality Data: An Analysis of Data From the ERA-EDTA Registry. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 468-474.	1.7	5
191	Timing of Fistula Creation and the Probability of Catheter-Free Use: A Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2019, 6, 205435811984313.	0.6	5
192	In-center nocturnal hemodialysis improves health-related quality of life for patients with end-stage renal disease. <i>Journal of Nephrology</i> , 2021, , 1.	0.9	5
193	Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome: study protocol. <i>BMJ Open</i> , 2021, 11, e052450.	0.8	5
194	Pharmacological interventions for heart failure in people with chronic kidney disease. <i>The Cochrane Library</i> , 2016, , .	1.5	4
195	Investigating the Relationship Between Age and Kidney Failure in Adults With Category 4 Chronic Kidney Disease. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812096681.	0.6	4
196	Association Between Attempted Arteriovenous Fistula Creation and Mortality in People Starting Hemodialysis via a Catheter: A Multicenter, Retrospective Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812110328.	0.6	4
197	On Framing the Research Question and Choosing the Appropriate Research Design. <i>Methods in Molecular Biology</i> , 2015, 1281, 3-18.	0.4	4
198	Modeling Longitudinal Data, II: Standard Regression Models and Extensions. <i>Methods in Molecular Biology</i> , 2008, 473, 61-94.	0.4	4

#	ARTICLE	IF	CITATIONS
199	Dialysis Prescription in Elderly Hemodialysis Patients. <i>Journal of Vascular Access</i> , 2000, 1, 139-143.	0.5	3
200	Early Failure Rates of Arterovenous Fistulas for Hemodialysis: Evaluation of Six-Year Activity. <i>Journal of Vascular Access</i> , 2001, 2, 154-160.	0.5	3
201	Clinical research of kidney diseases 1: researchable questions and valid answers. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2459-2468.	0.4	3
202	Willingness to Participate in a Randomized Trial Comparing Catheters to Fistulas for Vascular Access in Incident Hemodialysis Patients: An International Survey of Nephrologists. <i>Canadian Journal of Kidney Health and Disease</i> , 2016, 3, 125.	0.6	3
203	The attributes of an effective teacher differ between the classroom and the clinical setting. <i>Advances in Health Sciences Education</i> , 2016, 21, 833-840.	1.7	3
204	Graft Function, Albuminuria, and the Risk of Hemorrhage and Thrombosis After Kidney Transplantation. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812095219.	0.6	3
205	Nephrology consultation and kidney failure in people with stage 4 chronic kidney disease: a population-based cohort study. <i>Journal of Nephrology</i> , 2020, 34, 1225-1234.	0.9	3
206	Four steps to standardize reporting of peritoneal dialysis technique failure: A proposed approach. <i>Peritoneal Dialysis International</i> , 2020, , 089686082097693.	1.1	3
207	Clinical Correlates and Outcomes of Dual Basiliximab and Antithymocyte Globulin Induction in Kidney Transplant Recipients: A National Study. <i>Transplantation Direct</i> , 2021, 7, e736.	0.8	3
208	A pilot randomised controlled trial of an energy management programme for adults on maintenance haemodialysis: the fatigue-HD study. <i>BMJ Open</i> , 2022, 12, e051475.	0.8	3
209	Association of a Change in Erythropoiesis-Stimulating Agent Dose During Hospitalization and Subsequent Hemoglobin Levels and Transfusions in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2013, 62, 947-952.	2.1	2
210	Controversies in vascular access. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 209-213.	1.0	2
211	Longitudinal Studies 3: Data Modeling Using Standard Regression Models and Extensions. <i>Methods in Molecular Biology</i> , 2015, 1281, 93-131.	0.4	2
212	Risks of Changing Estimated Glomerular Filtration Rate Thresholds in Older Personsâ€”Reply. <i>JAMA Internal Medicine</i> , 2022, 182, 239.	2.6	2
213	A nephrology guide to reading and using systematic reviews of observational studies. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1615-1621.	0.4	1
214	Effects of longitudinal changes in Charlson comorbidity on prognostic survival model performance among newly diagnosed patients with hypertension. <i>BMC Health Services Research</i> , 2016, 16, 671.	0.9	1
215	Extracellular fluid management and hypertension in urban dwelling versus rural dwelling hemodialysis patients. <i>Journal of Nephrology</i> , 2018, 31, 103-110.	0.9	1
216	Secular Changes in Mortality and Hospitalization over Time in People with Kidney Failure or Severe CKD as Compared with Other Noncommunicable Diseases. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2631-2641.	3.0	1

#	ARTICLE	IF	CITATIONS
217	Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients Treated With Both Basiliximab and Antithymocyte Globulin. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812096406.	0.6	1
218	The Association Between Estimated Glomerular Filtration Rate and Hospitalization for Fatigue: A Population-Based Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812110012.	0.6	1
219	Training clinicians in a problem-solving fatigue programme for patients receiving maintenance haemodialysis. <i>Journal of Renal Care</i> , 2021, , .	0.6	1
220	On Framing the Research Question and Choosing the Appropriate Research Design. <i>Methods in Molecular Biology</i> , 2021, 2249, 1-16.	0.4	1
221	Longitudinal Studies 2: Modeling Data Using Multivariate Analysis. <i>Methods in Molecular Biology</i> , 2021, 2249, 103-124.	0.4	1
222	Internal Medicine residents use heuristics to estimate disease probability. <i>Canadian Medical Education Journal</i> , 2015, 6, e71-7.	0.3	1
223	The availability of support and peritoneal dialysis survival: A cohort study. <i>Peritoneal Dialysis International</i> , 2022, , 089686082210867.	1.1	1
224	More Infiltration in Less Mature Fistulae?. <i>American Journal of Kidney Diseases</i> , 2006, 48, 181.	2.1	0
225	Association Between Attempted Arteriovenous Fistula Creation and Mortality in Patients Starting Hemodialysis Via a Catheter: A Multicenter, Canadian, Retrospective Cohort Study. <i>Journal of Vascular Surgery</i> , 2020, 72, e354-e355.	0.6	0
226	Ofatumumab or Rituximab for Children with Steroid- and Calcineurin Inhibitor -Dependent Nephrotic Syndrome - <i>A Superiority Randomized Controlled Trial (OFA2)</i>. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
227	Longitudinal Studies 3: Data Modeling Using Standard Regression Models and Extensions. <i>Methods in Molecular Biology</i> , 2021, 2249, 125-165.	0.4	0
228	Inadequate Dosage of Mycophenolate Mofetil Is Likely to Yield Substandard Trial Results and Substandard Patient Care—Reply. <i>JAMA Pediatrics</i> , 2021, 175, 870.	3.3	0
229	Acute renal failure after right nephrectomy for spontaneous rupture and left renal vein ligation. <i>Clinical Nephrology</i> , 2005, 64, 167-170.	0.4	0
230	Modeling Longitudinal Data, I: Principles of Multivariate Analysis. <i>Methods in Molecular Biology</i> , 2008, 473, 39-60.	0.4	0
231	A miRNA Risk Score for the Prediction of Response to Rituximab-CHOP Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010, 116, 324-324.	0.6	0
232	Longitudinal Studies 2: Modeling Data Using Multivariate Analysis. <i>Methods in Molecular Biology</i> , 2015, 1281, 71-92.	0.4	0
233	Regulatory T Cells and Oxidative Stress in Minimal Change Nephropathy. , 2016, , 93-103.		0
234	Location, Location, Location: Usual Source of Care, Kidney Disease Outcomes, and the Social Determinants of Health. <i>Kidney Medicine</i> , 2022, 4, 100430.	1.0	0

#	ARTICLE	IF	CITATIONS
235	Immunosuppressive therapy for IgA nephropathy in children. The Cochrane Library, 2022, 2022, .	1.5	0
236	Reply to: "On the Importance of Considering Glycosylation when Evaluating Biologics", Journal of the American Society of Nephrology: JASN, 2022, 33, ASN.2022050534.	3.0	0